Logo
x

Search category

Subscribe Now

Advanced Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carci...

  • August 12, 2021
Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carci...

  • August 12, 2021
PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced...

  • May 11, 2021
PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced...

  • May 11, 2021
Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal Cell Carcinoma and Endometrial Carcinoma

Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal C...

  • May 7, 2021
Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal Cell Carcinoma and Endometrial Carcinoma

Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal C...

  • May 7, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.